GW501516 in dyslipidemia
Reported changes in lipid measures over 12 weeks.
Short-term; not powered for cancer or long-term safety.
Original source ↗Loading TrenasCycles…
TrenasCycles
Loading TrenasCycles…
Investigational PPAR-delta agonist
GW1516
Cardarine's reported appeal is better endurance, not muscle growth or fullness. It is neither a steroid nor a SARM. Human research found improved cholesterol markers, not proven sporting endurance or heart protection. Serious animal toxicities stopped development, so better-looking bloodwork does not mean a steroid cycle has become safe.
Small human metabolic studies reported lipid changes, while long-term safety is unresolved and animal carcinogenicity/toxicity concerns prevent a favorable risk conclusion.
Unknown long-term human safety; serious preclinical toxicity/cancer concern; possible liver or metabolic effects and counterfeit-product risk.
Liver markers and lipids may change, but monitoring does not establish safety or neutralize unknown cancer risk.
Never approved. Development was stopped after serious preclinical toxicity signals; prohibited in sport.
Other aliases: GW1516 · GW501516
Reported changes in lipid measures over 12 weeks.
Short-term; not powered for cancer or long-term safety.
Original source ↗Reported LDL/triglyceride changes; HDL was not clearly improved.
Small and short-term.
Original source ↗States development was stopped after serious preclinical toxicities.
Does not quantify human incidence.
Original source ↗Lists anabolic agents and metabolic modulators prohibited in sport.
Sport rule, not a medical-risk ranking.
Original source ↗